Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Current Deferred Revenue: 2016-2025

Historic Current Deferred Revenue for Collegium Pharmaceutical (COLL) over the last 3 years, with Sep 2025 value amounting to $667,000.

  • Collegium Pharmaceutical's Current Deferred Revenue fell 99.66% to $667,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $667,000, marking a year-over-year decrease of 99.66%. This contributed to the annual value of $191.5 million for FY2024, which is 27.82% up from last year.
  • Latest data reveals that Collegium Pharmaceutical reported Current Deferred Revenue of $667,000 as of Q3 2025, which was down 99.61% from $172.4 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Current Deferred Revenue registered a high of $197.8 million during Q3 2024, and its lowest value of $667,000 during Q3 2025.
  • Its 3-year average for Current Deferred Revenue is $151.3 million, with a median of $167.5 million in 2023.
  • Over the last 5 years, Collegium Pharmaceutical's Current Deferred Revenue had its largest YoY gain of 36.21% in 2025, and its largest YoY loss of 99.66% in 2025.
  • Collegium Pharmaceutical's Current Deferred Revenue (Quarterly) stood at $156.9 million in 2022, then dropped by 4.53% to $149.8 million in 2023, then grew by 27.82% to $191.5 million in 2024, then slumped by 99.66% to $667,000 in 2025.
  • Its last three reported values are $667,000 in Q3 2025, $172.4 million for Q2 2025, and $188.3 million during Q1 2025.